<code id='7F0F9B9CA1'></code><style id='7F0F9B9CA1'></style>
    • <acronym id='7F0F9B9CA1'></acronym>
      <center id='7F0F9B9CA1'><center id='7F0F9B9CA1'><tfoot id='7F0F9B9CA1'></tfoot></center><abbr id='7F0F9B9CA1'><dir id='7F0F9B9CA1'><tfoot id='7F0F9B9CA1'></tfoot><noframes id='7F0F9B9CA1'>

    • <optgroup id='7F0F9B9CA1'><strike id='7F0F9B9CA1'><sup id='7F0F9B9CA1'></sup></strike><code id='7F0F9B9CA1'></code></optgroup>
        1. <b id='7F0F9B9CA1'><label id='7F0F9B9CA1'><select id='7F0F9B9CA1'><dt id='7F0F9B9CA1'><span id='7F0F9B9CA1'></span></dt></select></label></b><u id='7F0F9B9CA1'></u>
          <i id='7F0F9B9CA1'><strike id='7F0F9B9CA1'><tt id='7F0F9B9CA1'><pre id='7F0F9B9CA1'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:2837
          Surrounded by tablets, an elder miniature figure walks with a cane next to a stethoscope — coverage from STAT
          Adobe

          Medicare Advantage is arguably the most controversial health care program right now — a sentiment that was bolstered Friday by striking new data about overpayments and an uncommon political jab during a routine meeting of policy wonks.

          The Medicare Payment Advisory Commission, a group that advises Congress on Medicare policy, gathered to discuss its pending March report on the state of Medicare Advantage, the alternative to traditional Medicare that is run by health insurance companies. Medicare Advantage is expected to cost taxpayers $507 billion this year, according to the latest federal estimates.

          advertisement

          The group, known as MedPAC, came to several familiar conclusions from the staff’s presentation and report: The federal government significantly overpays Medicare Advantage insurers because they attract healthier, lower-cost people into their plans and then excessively code those people’s health conditions — making Medicare Advantage a drain on taxpayers. MedPAC’s staffers also reiterated that Medicare Advantage’s quality rating system is “not a good basis for judging quality,” and therefore leads to further overpayments because insurers are paid bonuses based on this quality system.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Stanford president faces new allegations over 1999 paper
          Stanford president faces new allegations over 1999 paper

          Stanfordisinvestigationallegationsofresearchmisconductagainstitspresident,MarcTessier-Lavigne.AdamFa

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

          JOSEPHPREZIOSO/AFPviaGettyImagesLONDON—TheU.K.’scost-effectivenesswatchdogsaidThursdayitisnotyetreco